

DR GÖRAN ANDO



Göran has a multi-industry knowledge in healthcare, medicine, pharmaceuticals, biotechnology, and private equity. This has been acquired by over 30 years of international senior leadership experience as Chair and CEO. All this has allowed him to gain a vast wealth of experience and knowledge.

Dr Göran Ando MD was formerly Chair of Novo Nordisk A/S overseeing its transformational growth. He is Chair of Nouscom, Eyepoint Pharmaceuticals Inc. and Nanexa AB. In addition, Göran serves as an Advisor to edbi Pte Ltd, Singapore.

Göran is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. From 1989 to 1995, he was Medical Director, moving to Deputy R&D Director and then R&D Director of Glaxo Group Ltd. He was also a member of the Glaxo Group Executive Committee.

From 1995 to 2003 he was part of Pharmacia Corp, now Pfizer US, where he was Executive Vice President and President of R&D with additional responsibilities for manufacturing, IT, business development and mergers and acquisitions.

Göran was previously CEO of Celltech Group plc UK.



Major Career Roles

Former Chair, Novo Nordisk A/S
and Tessa Therapeutics

Chair, Nouscom

Chair, Eyepoint Pharmaceuticals
Inc.

Chair, Nanexa AB

Advisor, edbi Pte Ltd, Singapore

Other Career Highlights

Former Chair, Symphogen A/S

Former Board member, Selecta
Biosciences Inc